Active, Not Recruiting
Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
NCT04906993
- Conditions
- Cervical Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +11 more
- Locations
-
- Fudan University Shanghai Cancer Center Shanghai, Shanghai Municipality, China